Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Li, Wenjun ^a   Zheng, Liu ^b   Sheng, Chunjun ^a   Cheng, Xiaoyun ^a   Qing, Liu ^a,c   Qu, Shen ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shenzhen Hospital   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; INTERLEUKIN 6; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; AMINOTRANSFERASE; PHOSPHODIESTERASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LOW CALORY DIET; NAUSEA; NONALCOHOLIC FATTY LIVER; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; FATTY LIVER; METABOLISM;

CYTOKINES; FATTY LIVER; HUMANS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TRANSAMINASES;

EID: 79953763871     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-49     Document Type: Review

References (35)

1. Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation. JK Reddy MS Rao, Am J Physiol Gastrointest Liver Physiol 2006 290 852 G858 10.1152/ajpgi.00521.2005 16603729
2. Fatty liver and insulin resistance: not always linked. G Schonfeld P Yue X Lin Z Chen, Trans Am Clin Climatol Assoc 2008 119 217 23 discussion 223-4 18596860
3. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. VT Samuel ZX Liu X Qu BD Elder S Bilz D Befroy AJ Romanelli GI Shulman, Biol Chem 2004 279 32345 53 10.1074/jbc.M313478200 (Pubitemid 39014687)
4. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. C Postic J Girard, J Clin Invest 2008 118 829 38 10.1172/JCI34275 18317565 (Pubitemid 351364588)
5. Pathogenesis of non-alcoholic fatty liver disease. JK Dowman JW Tomlinson PN Newsome, QJM 2010 103 71 83 10.1093/qjmed/hcp158 19914930
6. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. JJ Maher P Leon JC Ryan, Hepatology 2008 48 670 8 10.1002/hep.22399 18666225
7. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. AE Feldstein A Canbay P Angulo M Taniai LJ Burgart KD Lindor GJ Gores, Gastroenterology 2003 125 437 443 10.1016/S0016-5085(03) 00907-7 12891546 (Pubitemid 36929425)
8. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. JM Schattenberg R Singh Y Wang JH Lefkowitch RM Rigoli PE Scherer MJ Czaja, Hepatology 2006 43 163 172 10.1002/hep.20999 16374858 (Pubitemid 43733603)
9. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. S Abiru K Migita Y Maeda M Daikoku M Ito K Ohata S Nagaoka T Matsumoto Y Takii K Kusumoto M Nakamura A Komori K Yano H Yatsuhashi K Eguchi H Ishibashi, Liver Int 2006 26 39 45 10.1111/j.1478-3231.2005.01191.x 16420507
10. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. IH Bahcecioglu M Yalniz H Ataseven N Ilhan IH Ozercan D Seckin K Sahin, Hepatogastroenterology 2005 52 1549 53 16201116 (Pubitemid 41391035)
11. Cellular mechanism of insulin resistance: potential links with inflammation. G Perseghin K Petersen GI Shulman, Int J Obes Relat Metab Disord 2003 27 Suppl 3 6 S11 10.1038/sj.ijo.0802491 14704736
12. Inflammation and insulin resistance. SE Shoelson J Lee AB Goldfine, J Clin Invest 2006 116 1793 1801 10.1172/JCI29069 16823477 (Pubitemid 44033299)
13. Role of inflammation in nonalcoholic steatohepatitis. S Choi AM Diehl, Curr Opin Gastroenterol 2005 21 702 7 10.1097/01.mog.0000182863.96421.47 16220049 (Pubitemid 41578647)
14. Cellular mechanism of insulin resistance: potential links with inflammation. G Perseghin K Petersen GI Shulman, Int J Obes Relat Metab Disord 2003 27 Suppl 3 6 S11 10.1038/sj.ijo.0802491 14704736
15. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. JY Lee DH Hwang, Mol Cell 2006 21 174 185
16. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. M Lorenzo S Fernndez-Veledo R Vila-Bedmar L Garcia-Guerra C De Alvaro I Nieto-Vazquez, J Anim Sci 2008 86 14 Suppl 94 104 17940160
17. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. AM Diehl, Clin Liver Dis 2004 8 619 638 10.1016/j.cld.2004.04.012 15331067 (Pubitemid 39141146)
18. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. A Desmouliere G Xu AM Costa IM Yousef G Gabbiani B Tuchweber, J Hepatol 1999 30 621 631 10.1016/S0168-8278(99)80192-5 10207803 (Pubitemid 29151903)
19. Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. PS Bahra GE Rainger JL Wautier GB Nash, Cell Biochem Funct 2001 19 249 257 10.1002/cbf.922 11746205 (Pubitemid 33097880)
20. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). YM Lee DS Sutedja CT Wai YY Dan MO Aung L Zhou CL Cheng A Wee SG Lim, Hepatol Int 2008 2 196 201 10.1007/s12072-008-9058-1 19669304 (Pubitemid 351650148)
21. Pentoxifylline for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized, Placebo-Controlled Study. W Buranawati Thoun-U-Thaisri C Pramoolsinsup N Wisedopas K Atamasirikul U Udomsubpayakul, Thai J Gastroenterol 2007 8 57 63
22. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1, Il-6, Il-8 and TNF- levels in nonalcoholic fatty liver. Tuncer Uygan H Dülger K Türkdoan MR ekerolu M Kösem, Eastyern Journal of Medicine 2003 8 27 32 (Pubitemid 38155608)
23. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. EF Georgescu M Georgescu, J Gastrointestin Liver Dis 2007 16 39 46 17410287 (Pubitemid 46548588)
24. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. LA Adams CO Zein P Angulo KD Lindor, Am J Gastroenterol 2004 99 2365 2368 10.1111/j.1572-0241.2004.40064.x 15571584 (Pubitemid 40039367)
25. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. SK Satapathy P Sakhuja V Malhotra BC Sharma SK Sarin, J Gastroenterol Hepatol 2007 22 5 634 8 17444848 (Pubitemid 46608380)
26. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. EM Brunt, Semin Diagn Pathol 2005 22 330 338 10.1053/j.semdp.2006.04. 002 16939061 (Pubitemid 44118640)
27. Pathology of nonalcoholic fatty liver disease. MM Yeh EM Brunt, Am J Clin Pathol 2007 128 837 847 10.1309/RTPM1PY6YGBL2G2R 17951208 (Pubitemid 350133997)
28. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. E Akriviadis R Botla W Briggs S Han T Reynolds O Shakil, Gastroenterology 2000 119 1637 48 10.1053/gast.2000.20189 11113085 (Pubitemid 32198689)
29. Nonalcoholic fatty liver disease. LA Adams P Angulo KD Lindor, CMAJ 2005 172 899 905 10.1503/cmaj.045232 15795412 (Pubitemid 40543601)
30. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. VW Wong HL Chan AY Hui KF Chan CT Liew FK Chan JJ Sung, Aliment Pharmacol Ther 2004 20 45 49 10.1111/j.1365-2036.2004.02012.x 15225170 (Pubitemid 38938718)
31. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. C Loguercio V De Girolamo I de Sio C Tuccillo A Ascione F Baldi G Budillon L Cimino A Di Carlo MP Di Marino F Morisco F Picciotto L Terracciano R Vecchione V Verde C Del Vecchio Blanco, J Hepatol 2001 35 568 74 10.1016/S0168-8278(01)00192-1 11690701 (Pubitemid 33078265)
32. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. JB Dixon PS Bhathal PE O'Brien, Gastroenterology 2001 121 91 100 10.1053/gast.2001.25540 11438497 (Pubitemid 32591518)
33. Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH. Mary E Rinella, Clinical trials.gov 2005
34. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. CA Matteoni ZM Younossi T Gramlich N Boparai YC Liu AJ McCullough, Gastroenterology 1999 116 1413 9 10.1016/S0016-5085(99)70506-8 10348825 (Pubitemid 29258890)
35. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Qing Liu Stig Bengmark Shen Qu, Lipids in Health and Disease 2010 9 42 10.1186/1476-511X-9-42 20426802